Taysha Gene Therapies, Inc.
TSHA Nasdaq· Biological Products, (No Diagnostic Substances)
Last close · Oct 23, 2026
$3.96
KIRA · Stoqly’s AI analyst, in plain words
- Taysha Gene Therapies, Inc. had $9.8M of revenue in fiscal 2025, up 17.3% on the year before.
- Its operating margin was −1,130.6%, down 33.1 pts: of every 100 in sales, about −1,131 is left after running the business.
- Taysha Gene Therapies, Inc. lost $109M in fiscal 2025.
- Free cash flow was −$93.8M in fiscal 2025, −960.1% of revenue.
- Taysha Gene Therapies, Inc. has $269M more cash than debt.
Market cap
$1.5B
P/E
—
Revenue
$9.8M
Net income
−$109M
Free cash flow
−$93.8M
Operating margin
−1,130.6%
Taysha Gene Therapies, Inc. in 30 seconds · fiscal 2025
Are sales growing?
+17.3%
Yes. Sales grew 17.3% last year.
Does it make a profit?
−1,115.3%
No. It lost money last year.
Does profit turn into cash?
−960.1%
No. It spent more cash than it brought in.
How healthy are the accounts?
4 / 8
Mixed. It passes 4 of 8 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Taysha Gene Therapies, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 19, 2026
- Legal name
- Taysha Gene Therapies, Inc.
- CIK
- 0001806310
Taysha Gene Therapies, Inc. · TSHA
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | — | $2.5M | $15.5M | $8.3M | $9.8M |
| Revenue growth | — | — | 517.5% | −46.1% | 17.3% |
| Operating margin | — | −6,492.7% | −468.8% | −1,097.6% | −1,130.6% |
| Net income | −$175M | −$166M | −$112M | −$89.3M | −$109M |
| Net margin | — | −6,635.3% | −722.1% | −1,071.6% | −1,115.3% |
| Diluted EPS | −$4.64 | −$3.78 | −$0.96 | −$0.36 | −$0.34 |
| Cash | |||||
| Cash from operations | −$117M | −$88.4M | −$73.0M | −$81.2M | −$93.1M |
| Capital expenditure | $15.3M | $20.6M | $3.9M | $0.4M | $0.7M |
| Free cash flow | −$132M | −$109M | −$76.9M | −$81.6M | −$93.8M |
| FCF margin | — | −4,356.9% | −497.6% | −979.2% | −960.1% |
| Share count change | 113.1% | 16.7% | 164.2% | 115.4% | 27.8% |
| Debt and strength | |||||
| Cash and short-term investments | $149M | $87.9M | $144M | $139M | $320M |
| Debt incl. finance leases | $37.2M | $39.4M | $41.6M | $44.7M | $50.5M |
| Shareholders' equity | $95.4M | $0.9M | $74.9M | $71.5M | $247M |
| Current ratio | 3.1x | 1.5x | 4.1x | 5.4x | 12.2x |
| Interest coverage | −121.3x | −42.8x | −14.5x | −896.7x | −1,753.9x |
| Returns and quality | |||||
| Return on equity | −100.7% | −344.7% | −294.0% | −121.9% | −68.5% |
| Return on tangible equity | −183.0% | −17,493.6% | −148.9% | −124.8% | −44.1% |
| Piotroski F-score | — | 1 | 5 | 3 | 4 |
| Altman Z'' | −4.9 | −17.3 | −7.4 | −10.5 | −0.5 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$6.7M
3 insiders
Of sales under plans
46%
$3.1M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Taysha Gene Therapies, Inc. · TSHA
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $3.96 a share, the company is worth $1.5B.
Source: SEC EDGAR XBRL filings (CIK 0001806310). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.